SteroTherapeutics
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
716 N Bethlehem Pike Ste 203, Spring Hou...Phone Number
(267) 300-0010Website
www.sterotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About SteroTherapeutics
SteroTherapeutics is focused on developing innovative drug therapies for orphan diseases, which are often life-threatening and affect fewer than 200,000 people in the U.S. Their lead program, ST-002, targets Cushing's syndrome, a condition caused by elevated cortisol levels, and aims to provide more effective treatments with fewer side effects. Additionally, they are working on ST-003, which targets Primary Sclerosing Cholangitis (PSC), a rare bile duct disorder that may also address comorbid inflammatory bowel disease (IBD). The company collaborates with leading academic institutions and organizations to advance their research and therapeutic development.Explore more
SteroTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SteroTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if SteroTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if SteroTherapeutics is spiking on competitors!
Funding: Get notified immidiatlly once SteroTherapeutics has new funding data
Website visits: Recent activity has been detected on your website
SteroTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on SteroTherapeutics recently announced quarterly report
Product Launch: Get notified when SteroTherapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if SteroTherapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SteroTherapeutics
Recommended Actions
Find VP level buyers at SteroTherapeutics
Find more new buyers
Compare Similar Companies to SteroTherapeutics
Compare insights from companies similar to SteroTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SteroTherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SteroTherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SteroTherapeutics.
SteroTherapeutics Tech Stack
A closer look at the technologies used by SteroTherapeutics
SteroTherapeutics News & Media
Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma
DOYLESTOWN, Pa., March 30, 2022 /PRNewswire/ -- Sterotherapeutics, LLC announced today that it has entered into an exclusive agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation for a license to novel compounds and methods for the treatment of multiple...SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients
SPRING HOUSE, Pa., Dec. 02, 2020 (GLOBE NEWSWIRE) -- SteroTherapeutics, LLC, a biopharmaceutical company developing new treatments for patients with rare diseases announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to complete a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for a non-aSteroTherapeutics Receives New U.S. Patent for treatment of non-alcoholic Steatohepatitis (NASH)
PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- SteroTherapeutics, a privately held biopharmaceutical company developing therapies for metabolic diseases focused on non-alcoholic steatohepatitis (NASH) and Cushing’s syndrome, announced today that they have received patent approval from the United States Patent and Trademark Office (USPTO) on methods and composition for treatment of non-alcoholic Steatohepatitis (NASH).
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SteroTherapeutics
Sign Up For FreeTo access detailed company insights
SteroTherapeutics is focused on developing innovative drug therapies for orphan diseases, which are often life-threatening and affect fewer than 200,000 people in the U.S. Their lead program, ST-002, targets Cushing's syndrome, a condition caused by elevated cortisol levels, and aims to provide more effective treatments with fewer side effects. Add... Read More
